Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PinG study of gonadotropin regimens for puberty induction in males with gonadotropin deficiency
ISRCTN39441321Phase 3Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of follitropin alfa and recombinant human chorionic gonadotrophin in hypogonadotropic hypogonadism (HH), Congenital Hypogonadotropic Hypogonadism (CHH) and hypopituitarism (4 arms), sponsored by Queen Mary University of London. Primary endpoint: Capacity for spermatogenesis. Started Aug 2025; status: recruiting.
02
Drugs
follitropin alfarecombinant human chorionic gonadotrophin
03
Conditions
hypogonadotropic hypogonadism (HH)Congenital Hypogonadotropic Hypogonadism (CHH)hypopituitarism
Beyond the preview
Go deeper on ISRCTN39441321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39441321.